

Financial Tear Sheet

Corporate Profile

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, [Subsys®](#), which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched [Subsys®](#), our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, [Subsys®](#) has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is [Dronabinol Oral Solution](#), a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market [Dronabinol Oral Solution](#) and any other future supportive care products, if approved, through our commercial organization.

Please see [full prescribing information](#) for [Subsys®](#) including the boxed warning.

SEC FILINGS

FILING DATE	FORM
08/17/17	4
08/16/17	3
08/14/17	4
08/10/17	4

INSYS Therapeutics, Inc.

Attn: Secretary of the Board of Directors
1333 South Spectrum Blvd, Suite 100
Chandler, AZ 85286
Phone: (602) 910-2617
Fax: (602) 910-2627

Stock Information

INSY (COMMON STOCK)	
Exchange	NASDAQ GS (US Dollar)
Price	\$9.02
Change (%)	▼ 0.16 (1.64%)
Volume	70,528
52 Week Low	\$8.70
Market Cap	\$666,628,253
Rolling EPS	-0.21
PE Ratio	0
Shares Outstanding	72,696,647
Data as of 08/21/17 12:41 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

DATE	TITLE
08/03/17	Insys Therapeutics Reports Second Quarter 2017 Results
07/31/17	Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription
07/20/17	Insys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017

Upcoming Events

There are currently no events scheduled.

Ownership Profile

SHAREHOLDERS				
	Holders	Value (\$MM)	% O/S	Shares
Institution	186	768.14	95.2	69,226,872
Mutual Fund	187	118.66	13.6	9,855,709
Insider *	9	2.23	0.3	194,888

*Insider values reflect direct beneficial ownership.

TOP HOLDERS				
	Shares Held	% O/S	Share Change	Filing Date
John N. Kapoor Trust	42,430,310	58.4	55,700	03/15/17
OrbiMed Advisors, LLC	6,171,440	8.5	100,000	06/30/17
Kapoor Children's 1992 Trust	4,557,950	6.3	0	03/15/17
BlackRock Institutional Trust Company, N.A.	2,451,684	3.4	26,105	06/30/17
The Vanguard Group, Inc.	2,333,254	3.2	-17,853	06/30/17
Kapoor (John N)	1,180,368	1.6	0	03/15/17
APG Asset Management	1,114,542	1.5	279,298	03/31/17
Folger Hill Asset Management LLC	780,283	1.1	-225,978	06/30/17
Mirae Asset Global Investments (USA) LLC	634,001	0.9	634,001	06/30/17
Horizons ETFs Management (Canada) Inc.	628,176	0.9	628,176	06/30/17